Effect of vaccination on SARS-CoV-2 reinfection risk: a case–control study in the Republic of Cyprus
暂无分享,去创建一个
C. Demetriou | A. Quattrocchi | P. Kolios | M. Athanasiadou | Theopisti Kyprianou | S. Soteriou | C. Tsioutis | A. Demetriou | Georgios K. Nikolopoulos | E. Anastasiou | I. Mamais | Valentinos Silvestros | F. Theophanous | Chryso Gregoriadou | Christos Ηaralambous | Ioanna Gregoriou | O. Kalakouta | T. Kyprianou
[1] O. A. Ogun,et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.
[2] M. Nussenzweig,et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape , 2021, Nature.
[3] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months , 2021, The New England journal of medicine.
[4] D. Thoroughman,et al. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[5] M. C. Muenker,et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity , 2021, Nature.
[6] J. Ioannidis,et al. SARS‐CoV‐2 re‐infection risk in Austria , 2021, medRxiv.
[7] Yi Bai,et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans , 2020, Research square.
[8] 北村 聖. "The New England Journal of Medicine". , 1962, British medical journal.